Clinics in Dermatology
Volume 24, Issue 5 , Pages 348-362 , September 2006

Lupus erythematosus: systemic and cutaneous manifestations

  • Naomi Rothfield, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 860 679 3604, +1 860 679 2160; fax: +1 860 679 1287.
    • ,
  • Richard D. Sontheimer, MD

      Affiliations

    • Department of Dermatology and Residency Training Program, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    • Tel.: + 1 405 271 4662; fax: +1 405 271 7216.
    • ,
  • Megan Bernstein, MD

      Affiliations

    • University of Connecticut Health Center, Farmington, CT 06030, USA

References 

  1. Rothfield NF. Systemic lupus erythematosus: clinical aspects and treatment. In:  McCarthy EJ editors. Arthritis and allied conditions: a textbook of rheumatology. 11th ed.. Philadelphia: Lea & Febiger; 1989;p. 1022–1048
  2. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In:  Sontheimer RD,  Provost TT editor. Cutaneous manifestations of rheumatic diseases. 2nd ed.. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 15–64
  3. Costner MI, Sontheimer RD. Lupus erythematosus. In:  Freedberg IM,  Eisen AZ,  Wolff K,  Austen KF,  Goldsmith LA,  Katz SI editor. Fitzpatrick's dermatology in general medicine. 6th ed.. New York: McGraw-Hill; 2003;p. 1677–1693
  4. Peterson KS, Wincester RJ. Systemic lupus erythematous: pathogenesis. In:  Kooperman WJ editors. Arthritis and allied conditions. Philadelphia: Lipincott Williams & Wilkins; 2000;p. 1
  5. Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41:1161–1172
  6. Sontheimer RD. The lexicon of cutaneous lupus erythematosus—a review of personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997;6:84–95
  7. Pinkus H. Lichenoid tissue reactions: a speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans. Arch Dermatol. 1973;107:840–846
  8. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine. 1993;72:113–124
  9. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58–68
  10. Grant JM. Annular vesicular lupus erythematosus. Cutis. 1981;28:90–92
  11. Wechsler HL, Stavrides A. Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic and immunologic findings. J Am Acad Dermatol. 1982;6:73–83
  12. Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol. 1987;16:1265–1267
  13. Hymes SR, Russell TJ, Jordon RE. The anti-Ro antibody system. Int J Dermatol. 1986;25:1–7
  14. Scheinman PL. Acral subacute cutaneous lupus erythematosus: an unusual variant. J Am Acad Dermatol. 1994;30:800–801
  15. DeSpain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol. 1988;19:388–392
  16. Geraminejad P, Stone MS, Sontheimer RD. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus. Lupus. 2004;13:473–477
  17. Magro MC, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive and pathologic entity. J Cutan Pathol. 1988;2:72–78
  18. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev. 2005;4:296–302
  19. Sontheimer RD, Maddison PJ, Reichlin M, Jordan RE, Stasny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664–671
  20. Mond CB, Peterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum. 1989;32:202–204
  21. Bangert JL, Freeman RG, Sontheimer RD, Gilliam JN. Subacute cutaneous lupus erythematosus and discoid lupus erythematosus. Comparative histopathologic findings. Arch Dermatol. 1984;120:332–337
  22. Herrero C, Bielsa I, Font J, et al. Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol. 1988;19:1057–1062
  23. Prystowsky SD, Herndon JH, Gilliam JN. Chronic cutaneous lupus erythematosus (DLE): a clinical and laboratory investigation of 80 patients. Medicine (Baltimore). 1975;55:183–191
  24. Wilson CL, Burge SM, Dean D, Dawber RPR. Scarring alopecia in discoid lupus erythematosus. Br J Dermatol. 1992;126:307–314
  25. Sontheimer RD. Clinical manifestations of cutaneous lupus erythematosus. In:  Wallace DJ,  Hahn BH editor. Dubois' lupus erythematosus. 4th ed.. Philadelphia: Lea & Febiger; 1993;p. 285
  26. Kanwar J, Dhar S, Ghosh S. Involvement of nails in discoid lupus erythematosus. J Assoc Phys India. 1993;41:543
  27. Ashinoff R, Werth VP, Franks AG. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol. 1988;19:961–965
  28. Parrish LC, Kennedy RJ, Hurley HJ. Palmar lesions in lupus erythematosus. Arch Dermatol. 1967;96:273–276
  29. Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev. 2005;4:219–223
  30. Rowell NR, Goodfield MJD. The “connective tissue diseases”. In:  Champioin RH,  Burton JL,  Ebling FJG editor. Textbook of dermatology. London: Blackwell Scientific Publications; 1992;p. 2163
  31. Wolska H, Blaszczyk M, Jablonska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol. 1989;28:98–103
  32. Velthuis PJ, Van Weelden H, Van Wichen D, De la Faille HB. Immunohistopathology of light-induced skin lesions in lupus erythematosus. Acta Derm Venereol (Stockh). 1990;70:93–98
  33. Lehmann P, Holzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 1990;22(2 Pt 1):181–187
  34. Nived O, Johansen PB, Sturfelt G. Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus. Lupus. 1993;2:247–250
  35. Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation–induced injury, chemokines, and leukocyte recruitment. An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52:1504–1516
  36. Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases. J Cutan Pathol. 2005;32:396–404
  37. Requena L, Sanchez Yus E. Panniculitis (Part II). Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325
  38. Caproni M, Palleschi GM, Papi C, Fabbri P. Discoid lupus erythematosus lesions developed on lupus erythematosus profundus nodules. Int J Dermatol. 1995;34:357–359
  39. Carducci M, Mussi A, Lisi S, Muscardin L, Solivetti FM. Lupus mastitis: a 2-year history of a single localization of lupus erythematosus mimicking breast carcinoma. J Eur Acad Dermotol Venereol. 2005;19:260–262
  40. Ruiz H, Sanchez JL. Tumid lupus erythematosus. Am J Dermatopathol. 1999;21:356–360
  41. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus—review of 60 patients. Photochem Photobiol. 2001;73:532–536
  42. Diogenes MJ, Diogenes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol. 2004;43:632–637
  43. Weinstein C, Miller MH, Axtens R, Littlejohn GO, Dorevitch AP, Buchman R. Lupus and nonlupus cutaneous manifestations in systemic lupus erythematosus. Aust N Z J Med. 1987;17:501–506
  44. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Balitimore). 1989;68:366–374
  45. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum. 1992;21:275–276
  46. Burnham TK, Neblett JR, Fine G. The application of fluorescent antibody technique to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol. 1963;41:451
  47. Smith CD, Marino C, Rothfield NF. The clinical utility of the lupus band test. Arthritis Rheum. 1984;27:382–387
  48. Burnham TK, Fine G. The immunofluorescent band test for LE: III. Employing clinically normal skin. Arch Dermatol. 1971;103:24–32
  49. Bullock WE, Callerame ML, Panner BJ. Immunohistologic alternational skin and ultrastructural changes in glomerular membrane in leprosy. Am J Trop Med Hyg. 1974;23:78–86
  50. Font J, Cervera R, Navarro M, et al. Systemic lupus erythematosus in men: clinical and immunological characteristics. Ann Rheum Dis. 1992;51:1050–1052
  51. Rothfield N, Marino C. Studies of repeat skin biopsies of nonlesional skin in patients with systemic lupus erythematosus. Arthritis Rheum. 1982;25:624–630
  52. Matsopoulis HM, et al. Correlative histologic and serologic findings of sicca syndrome in patients with systemic lupus erythematosus. Arthritis Rheum. 1980;23:36–40
  53. Laurence J, Nachman R. Hematologic aspects of systemic lupus erythematosus. In:  Lahita RG editors. Systemic lupus erythematosus. New York: John Wiley & Sons, Inc; 1987;p. 721–790
  54. Ginzler EM, Dvorkina O. Newer therapeutic approaches for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005;31:315–328
  55. Fessler BJ, Alarcon GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473
  56. Lakshiminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102–108
  57. Traynor AE, Barr WG, Rose RM, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002;46:2917
  58. Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:359
  59. Petri M, Jones RG, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 2003;48:166
  60. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673
  61. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti–B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005;17:550
  62. Leandro MJ, Cambridge G, Edwards JC. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542
  63. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580
  64. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501
  65. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:2924
  66. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50:2852
  67. Sontheimer RD. Subacute cutaneous lupus erythematosus: a quarter century's perspective. In:  Sarzi-Puttini P,  Doria A,  Girolomoni G,  Kuhn A editor. The skin in systemic autoimmune diseases. Amsterdam: Elsevier; 2006;p. 65–86
  68. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4:253–263
  69. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103:49–51
  70. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59–65
  71. Matthes T, Hagedorn M. Terbinafine-induced subacute cutaneous lupus erythematosus. Case report and review of the literature. [German] Hautarzt. 2004;55:653–657
  72. Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45–49
  73. Shapiro M, Sosis AC, Junkins-Hopkins JM, et al. Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual. Int J Dermatol. 2004;43:87–94
  74. Ting WW, Sontheimer RD. Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus. 2001;10:171–184
  75. Herzinger T, Plewig G. Use of sunscreens to protect against ultraviolet induced lupus erythematosus. Arthritis Rheum. 2004;50:3045–3046
  76. Kaye ET, Levin JA, Blank IH, et al. Efficiency of opaque photoprotective agents in the visible light range. Arch Dermatol. 1991;127:351–355
  77. Boehncke WH, Ochsendorf F, Paeslack I, et al. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol. 2002;12:577–580
  78. Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12:50–52
  79. Walker SL, Kirby B, Chalmers RJG. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol. 2002;147:405–406
  80. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51:407–410
  81. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2001;CD002954
  82. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127:513–518
  83. Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus. 2000;9:92–95
  84. Chung HS, Hann SK. Lupus panniculitis treated with a combination therapy of hydroxychloroquine and quinacrine. J Dermatol. 1997;24:569–572
  85. Lipsker D, Piette J-C, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology. 1995;190:257–258
  86. Feldmann R, Salomon D, Saurat J-H. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology. 1994;189:425–427
  87. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002;109:1377–1382
  88. Anonymous . Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39:723–731
  89. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a re-examination. Semin Arthritis Rheum. 1989;18:282–297
  90. Holtman JH, Neustadt DH, Klein J, et al. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol. 1990;17:1222–1225
  91. Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 1986;11:102–103
  92. McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol. 1984;11:397–401
  93. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol. 1990;29:587–590
  94. Volc-Platzer B, Wolff K. Treatment of subacute cutaneous lupus erythematosus with thalidomide. Hautarzt. 1983;34:175–178
  95. Naafs B, Bakkers EJM, Flinterman J, et al. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol. 1982;107:83–86
  96. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol. 1986;115:211–216
  97. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol. 1974;91:93–96
  98. McGrath H, Bak E, Michalski JP. Ultraviolet-A light prolongs survival and improves immune function in (New Zealand Black × New Zealand White) F1 hybrid mice. Arthritis Rheum. 1987;30:557–561
  99. McGrath H. Prospects for UV-A1 therapy as a treatment modality in cutaneous and systemic LE. Lupus. 1997;6:209–217
  100. Mcgrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus. 1996;5:269–274
  101. Polderman MC, Huizinga TW, Le Cessie S, et al. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112–115
  102. Nived O, Johansen PB, Sturfelt G. Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus. Lupus. 1993;2:247–250
  103. Fautrel B, Foltz V, Frances C, et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha–blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 2002;46:1408–1409
  104. Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006;54:892–895
  105. Saito K, Nawata M, Nakayamada S. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus. 2003;12:798–800
  106. Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol. 2003;28:366–368
  107. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148:602–603
  108. Perrotta S, Locatelli F, La Manna A, et al. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002;116:465–467
  109. Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142–144

PII: S0738-081X(06)00107-6

doi: 10.1016/j.clindermatol.2006.07.014

Clinics in Dermatology
Volume 24, Issue 5 , Pages 348-362 , September 2006

Article Tools

* Image Usage & Resolution